Diagnosis of ALK-positive anaplastic large cell lymphoma based on CD30 testing.
BC Cancer Agency and BC Cancer Research Centre, Vancouver, British Columbia.
Randy D
RD
Gascoyne
D000328:Adult; D000951:Antigens, Neoplasm / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D001706:Biopsy; D000079963:Brentuximab Vedotin; D003951:Diagnostic Errors; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage; D017730:Ki-1 Antigen / Q000032:analysis* / Q000037:antagonists & inhibitors; D008198:Lymph Nodes / Q000737:chemistry / Q000473:pathology; D017728:Lymphoma, Large-Cell, Anaplastic / Q000737:chemistry / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis; D008297:Male; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000032:analysis; D012074:Remission Induction
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D009363:Neoplasm Proteins; D000079963:Brentuximab Vedotin